A Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMC-003 for Injection in Healthy Postmenopausal Women

Phase 1 Recruiting 56 enrolled ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

this study is a randomized, double-blind, placebo-controlled, single and multiple dose escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IMC-003 for injection in healthy postmenopausal women.

Timeline

Start: 2025-08-18
Primary completion: 2027-05-20
Completion: 2027-08-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	IMC-003	Unknown	—	—

Indications

No indication recorded.